AltimmuneALT
ALT
About: Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Employees: 59
0
Funds holding %
of 6,794 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
39% more call options, than puts
Call options by funds: $11.8M | Put options by funds: $8.53M
24% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 46
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
3% less funds holding
Funds holding: 172 [Q2] → 166 (-6) [Q3]
6.04% less ownership
Funds ownership: 61.59% [Q2] → 55.54% (-6.04%) [Q3]
17% less capital invested
Capital invested by funds: $290M [Q2] → $242M (-$48.5M) [Q3]
21% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 28
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
32%
upside
Avg. target
$19
109%
upside
High target
$26
185%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio 36% 1-year accuracy 51 / 142 met price target | 32%upside $12 | Buy Reiterated | 14 Nov 2024 |
UBS Eliana Merle 38% 1-year accuracy 5 / 13 met price target | 185%upside $26 | Buy Initiated | 12 Nov 2024 |
Financial journalist opinion
Based on 11 articles about ALT published over the past 30 days
Positive
CNBC Television
4 days ago
Altimmune CEO on what's next for its experimental obesity drug
Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, potential commercial partnership and more.
Positive
Zacks Investment Research
5 days ago
Altimmune Stock Up More Than 25% in a Month: Here's Why
ALT's recent progress related to the development of the lead product candidate, pemvidutide, for treating obesity and MASH is aiding the stock.
Neutral
GlobeNewsWire
1 week ago
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences:
Neutral
CNBC Television
2 weeks ago
Final Trade: C, NVDA, XLF, ALT
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Neutral
GlobeNewsWire
3 weeks ago
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids
Positive
Seeking Alpha
3 weeks ago
Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge
Results from the phase 2b IMPACT study, using Pemvidutide for the treatment of patients with MASH, expected Q2 of 2025. The global metabolic dysfunction-associated steatohepatitis market size is expected to reach $7.64 billion by 2031. Successful EOP2 meeting with FDA, of Pemvidutide for treatment of patients with obesity, brings about four phase 3 trial initiations in the coming year.
Positive
Seeking Alpha
3 weeks ago
Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health
Altimmune, Inc.'s Pemvidutide shows promise as a dual-action treatment for obesity and MASLD/MASH, targeting weight loss, liver health, and cardiovascular support. Their Phase 2 MOMENTUM trial for obesity demonstrated significant weight loss and lean mass preservation, with up to 15.6% weight reduction at the highest dose. Altimmune's cash runway is estimated to support operations into 1H2026, aligning with expected milestones and anticipated Phase 3 trials.
Neutral
Seeking Alpha
3 weeks ago
Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript
Altimmune, Inc. (NASDAQ:ALT ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Lee Roth - Burns McClellan, Investor Relations Advisors, Altimmune Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Andrew Shutterly - Acting Chief Financial Officer Ray Jordt - Chief Business Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Liisa Bayko - Evercore William Wood - B. Riley Securities Operator Good day, ladies and gentlemen, and welcome to Altimmune, Inc. Third Quarter 2024 Financial Results Conference Call.
Neutral
GlobeNewsWire
3 weeks ago
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), effective immediately. Mr. Weaver will lead the Company's finance and accounting functions, including SEC reporting and investor relations.
Neutral
GlobeNewsWire
3 weeks ago
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of Directors granted equity awards under Altimmune's 2018 Inducement Grant Plan, as a material inducement to employ Gregory Weaver as Altimmune's Chief Financial Officer effective November 11, 2024. The equity awards were approved on November 6, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
Charts implemented using Lightweight Charts™